WO2009022063A2 - Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents
Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDFInfo
- Publication number
- WO2009022063A2 WO2009022063A2 PCT/FR2008/000932 FR2008000932W WO2009022063A2 WO 2009022063 A2 WO2009022063 A2 WO 2009022063A2 FR 2008000932 W FR2008000932 W FR 2008000932W WO 2009022063 A2 WO2009022063 A2 WO 2009022063A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- branched
- linear
- pharmaceutically acceptable
- Prior art date
Links
- 0 COc(ccc1ccc2)cc1c2C(C*)=O Chemical compound COc(ccc1ccc2)cc1c2C(C*)=O 0.000 description 1
- FQOHMDPQTPNTEK-UHFFFAOYSA-N COc1cc(c(CCOS(C)(=O)=O)ccc2)c2cc1 Chemical compound COc1cc(c(CCOS(C)(=O)=O)ccc2)c2cc1 FQOHMDPQTPNTEK-UHFFFAOYSA-N 0.000 description 1
- DWMKOIBVRRVBRW-UHFFFAOYSA-N COc1cc2c(C(C#N)O[Si](C)(C)C)cccc2cc1 Chemical compound COc1cc2c(C(C#N)O[Si](C)(C)C)cccc2cc1 DWMKOIBVRRVBRW-UHFFFAOYSA-N 0.000 description 1
- BBVBSSQKNOJKBQ-UHFFFAOYSA-N COc1ccc(cccc2C=C)c2c1 Chemical compound COc1ccc(cccc2C=C)c2c1 BBVBSSQKNOJKBQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to novel naphthalenic derivatives, process for their preparation and pharmaceutical compositions containing them.
- the compounds of the present invention are novel and have very interesting pharmacological characteristics concerning melatoninergic receptors.
- melatonin N-acetyl-5-methoxytryptamine
- melatonin analogues which are metabolically more stable and have an agonist or antagonist character, which can be expected to have a therapeutic effect greater than that of the hormone itself.
- the melatoninergic system ligands possess interesting pharmacological properties on the central nervous system, including anxiolytics and antipsychotics
- the compounds of the present invention in addition to their novelty, show a very high affinity for melatonin receptors.
- the present invention relates more particularly to the compounds of formula (I):
- R 1 represents an alkyl (Ci-C 6) linear or branched, alkenyl (Ci-C 6) linear or branched haloalkyl (Ci-C 6) linear or branched polyhaloalkyl (Ci-C 6) linear or branched cycloalkyl (C 3 -C 8 ), cycloalkyl (C 3 -C 8 ) alkyl (C 1 -C 6 ), the alkyl portion may be linear or branched, aryl, aryl (C 1 -C 6 ) alkyl, the alkyl part may be linear or branched , heteroaryl or heteroarylalkyl (Ci-C 6 ) whose alkyl part may be linear or branched
- X represents an N-OR 2 group in which R 2 represents a hydrogen atom or a linear or branched (C 1 -C 6 ) alkyl group,
- aryl means a phenyl, naphthyl or biphenyl group
- heteroaryl any mono or bicyclic aromatic group containing 1 to 3 heteroatoms chosen from oxygen, sulfur and nitrogen, the aryl and heteroaryl groups thus defined being capable of being substituted with 1 to 3 groups chosen from alkyl (C 1 -C 6) linear or branched alkoxy (C 1 -C 6) linear or branched, hydroxy, carboxy, formyl, nitro, cyano, halo (C 1 -C 6) linear or branched polyhaloalkyl (C 1 -C 6) -straight or branched, alkyloxycarbonyl, or halogen atoms,
- hydrochloric hydrobromic, sulfuric, phosphonic, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, oxalic and methane acids. sulfonic, camphoric, etc.
- pharmaceutically acceptable bases mention may be made, without limitation, of sodium hydroxide, potassium hydroxide, triethylamine, tertbutylamine, and the like.
- the preferred compounds of the invention are the compounds of formula (I) for which R 1 represents a linear or branched (Ci-C 6 ) alkyl group such as, for example, the methyl group.
- the group R 2 represents a hydrogen atom or a methyl group. - AT -
- the invention relates to compounds which are N - [(2E) -2- (hydroxyimino) -2- (7-methoxy-1-naphthyl) ethyl] acetamide, iV - [(2Z) -2 - (hydroxyimino) -2- (7-methoxy-1-naphthyl) ethyl] acetamide, and N - [(2E) -2- (methoxyimino) -2- (7-methoxy-1-naphthyl) ethyl] acetamide.
- the invention also extends to the process for the preparation of the compound of formula (I), characterized in that the compound of formula (II) used is the starting material:
- the pharmacological study of the derivatives of the invention has shown that they are atoxic, endowed with a high selective affinity for melatonin receptors and have important activities on the central nervous system and, in particular, have been noted.
- therapeutic properties on sleep disorders, antidepressant, anxiolytic, antipsychotic, analgesic and microcirculation properties which make it possible to establish that the products of the invention are useful in the treatment of stress, sleep disorders, anxiety, seasonal depression or major depression, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet lag, schizophrenia, panic attacks, melancholy, disorders of the appetite, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders related to normal or pathological aging, migraine, memory loss, Alzheimer's disease, as well as disorders of the cerebral circulation.
- the products of the invention can be used in malfunctions they possess the properties of ovulation inhibitors, immunomodulators and that they are likely to
- the compounds will preferably be used in the treatment of major depression, seasonal depression, sleep disorders, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet lag, appetite disorders and obesity.
- the compounds will be used in the treatment of major depression, seasonal depression and sleep disorders.
- the present invention also relates to pharmaceutical compositions containing at least one compound of formula (I) alone or in combination with one or more pharmaceutically acceptable excipients.
- compositions according to the invention mention may be made, more particularly, of those which are suitable for oral, parenteral, nasal, percutaneous, rectal, perlingual, ocular or respiratory administration and in particular simple or coated tablets, sublingual tablets. , sachets, packets, capsules, glossettes, lozenges, suppositories, creams, ointments, dermal gels, and oral or injectable ampoules.
- the dosage varies according to the sex, age and weight of the patient, the route of administration, the nature of the therapeutic indication, or possibly associated treatments and ranges between 0.01 mg and 1 g per 24 hours. in one or more takes.
- Example 1 7V - [(2Z) -2- (Hydroxyimino) -2- (7-methoxy-1-naphthyl) ethyl] acetamide
- Step A 2- (7-Methoxy-1-naphthyl) ethyl methanesulfonate
- Step A The compound obtained in Step A (21.4 mmol) is dissolved in 120 ml of tetrahydrofuran and potassium t-butoxide (64.2 mmol) is added in small portions. After stirring for 30 minutes at room temperature, the reaction medium is evaporated to dryness. The residue obtained is taken up in 150 ml of water and the aqueous phase is extracted with twice 60 ml of diethyl ether. The organic phase is washed with water, dried over magnesium sulfate, decolorized on vegetable charcoal and evaporated. The residue obtained is purified on silica gel (eluent: petroleum ether) to yield the title product in the form of a yellow oil.
- silica gel eluent: petroleum ether
- the methyltriphenylphosphonium iodide (5.7 mmol) is dissolved in 250 ml of anhydrous dichloromethane, under argon, and then the trimethylsilyl cyanide (170.8 mmol) and the compound obtained in Stage C (56.9 mmol). are added.
- the reaction medium is stirred at ambient temperature for 72 hours and then 200 ml of water are added.
- the two phases are separated and the aqueous phase is extracted with 50 ml of dichloromethane.
- the organic phases are combined, dried over magnesium sulphate and evaporated under reduced pressure.
- the precipitate is filtered off with ether and recrystallized from cyclohexane to yield the title product as a white solid. Melting point: 123-125 ° C
- lithium aluminum hydride (37.1 mmol) is suspended in 200 ml of diethyl ether.
- the compound obtained in Stage D (18.6 mmol), solubilized in 50 ml of tetrahydrofuran, is added dropwise.
- the reaction medium is stirred at room temperature for 1 hour.
- the excess lithium aluminum hydride is destroyed by successive additions of 1.4 ml of water, 1.4 ml of 15% sodium hydroxide and 4.2 ml of water.
- the formed mineral precipitate is removed by filtration and washed with 50 ml of tetrahydrofuran.
- the filtrate is dried over magnesium sulphate and evaporated under reduced pressure.
- Step E The compound obtained in Step E (20 mmol) is dissolved in a water / ethyl acetate mixture (25 ml / 75 ml) cooled to 0 ° C. Potassium carbonate (60 mmol) is added and the acetyl chloride (26 mmol) is added dropwise to the reaction medium. The whole is stirred vigorously for 30 minutes at room temperature. The two phases are separated and the organic phase is washed with a 0.1M aqueous hydrochloric acid solution and then with water. After drying over magnesium sulphate, the organic phase is evaporated under reduced pressure. The resulting residue is recrystallized from acetonitrile to yield the title product as a white solid. Melting point: 173-175 ° C
- Step G the compound obtained in Step G (4.2 mmol) is dissolved in 25 ml of methanol. Hydroxylamine hydrochloride (16.8 mmol) and pyridine (21.1 mmol) are added and the reaction mixture is refluxed with magnetic stirring for 3 hours. After cooling, the reaction medium is poured into 50 ml of water. The precipitate formed is drained, washed with water and recrystallized from toluene to yield the title product in the form of a white solid. Melting point: 136-138 ° C
- Acute toxicity was assessed after oral administration to batches of 8 mice (26 ⁇ 2 grams). The animals were observed at regular intervals during the first day and daily for two weeks after treatment. The LD 50, resulting in the death of 50% of the animals, was evaluated and showed the low toxicity of the compounds of the invention.
- the compounds of the invention are tested in a behavioral model, the forced swimming test.
- the apparatus consists of a Plexiglas cylinder filled with water.
- the animals are tested individually during a 6-minute session. At the beginning of each test, the animal is placed in the center of the cylinder. The downtime is recorded. Each animal is judged immobile when it ceases to struggle, and remains on the surface of the water, motionless, making only the movements allowing it to keep its head out of the water.
- the compounds of the invention significantly reduce the duration of immobilization attesting to their antidepressant activity.
- the MT 1 or MT 2 receptor binding experiments are carried out using the
- the values of K; found for the compounds of the invention attest to a binding for one or the other melatoninergic binding sites, these values being ⁇ 10 .mu.M.
- the compound obtained in Example 2 has a Ki (MT 1 ) of 7 nM and a K 1 (MT 2 ) of 0.8 nM.
- the affinity of the compounds for human 5-HT receptor 2 c is evaluated on membrane preparations from CHO cells stably expressing that receptor.
- the incubation is carried out in 50 mM TRIS buffer, pH 7.4 containing 10 mM MgCl 2 and 0.1% BSA, in the presence of [ 3 H] mesulergine (1 nM) and 25 fmol / ml of receiver. Nonspecific binding is determined in the presence of 10 ⁇ M mianserin.
- the reaction is stopped by the addition of 50 mM TRIS buffer, pH 7.4 followed by a filtration step and 3 successive rinses: the radioactivity bound to the membranes remaining on the filters (GF / B pretreated with 0.1% PEI) is counted as liquid scintillation.
- One-month-old male rats are subjected to a light cycle of 12 hours of light per day as soon as they arrive at the laboratory (LD 12:12).
- the rats receive a daily administration of the molecule to be tested.
- the compounds of the invention are tested in a behavioral model, the light / dark cages test, which reveals the anxiolytic activity of the molecules.
- the device consists of two polyvinyl boxes covered with Plexiglas. One of these boxes is obscure. One lamp is placed above the other box giving a luminous intensity in the center of it of approximately 4000 lux. An opaque plastic tunnel separates the clear box from the dark box. The animals are tested individually during a 5 min session. The floor of each box is cleaned between each session. At the beginning of each test, the mouse is placed in the tunnel, facing the dark box. The time spent by the mouse in the lighted box and the number of transitions through the tunnel are recorded after the first entry in the dark box. After administration of the compounds 30 min before the start of the test, the compounds of the invention significantly increase the time spent in the illuminated cage and the number of transitions, which shows the anxiolytic activity of the derivatives of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201000083A EA201000083A1 (ru) | 2007-07-02 | 2008-07-01 | Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их |
AU2008288373A AU2008288373B2 (en) | 2007-07-02 | 2008-07-01 | Novel naphthalene derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
CA002691586A CA2691586A1 (fr) | 2007-07-02 | 2008-07-01 | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US12/452,429 US7947852B2 (en) | 2007-07-02 | 2008-07-01 | Naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them |
BRPI0814402-8A BRPI0814402A2 (pt) | 2007-07-02 | 2008-07-01 | Derivados naftalênicos, processo de preparação e composições farmacêuticas que os contêm |
CN200880022874A CN101687777A (zh) | 2007-07-02 | 2008-07-01 | 新的萘衍生物、其制备方法和含有它们的药物组合物 |
EP08827457A EP2167460A2 (fr) | 2007-07-02 | 2008-07-01 | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP2010514037A JP2010531859A (ja) | 2007-07-02 | 2008-07-01 | 新規ナフタレン誘導体、その製造法およびそれを含有する薬学的組成物 |
ZA2010/00024A ZA201000024B (en) | 2007-07-02 | 2010-01-04 | New naphthalene compounds,a process for their preparation and pharmaceutical compositions containing them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0704747A FR2918372B1 (fr) | 2007-07-02 | 2007-07-02 | Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR0704747 | 2007-07-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009022063A2 true WO2009022063A2 (fr) | 2009-02-19 |
WO2009022063A3 WO2009022063A3 (fr) | 2009-04-16 |
Family
ID=38925714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2008/000932 WO2009022063A2 (fr) | 2007-07-02 | 2008-07-01 | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Country Status (15)
Country | Link |
---|---|
US (1) | US7947852B2 (fr) |
EP (1) | EP2167460A2 (fr) |
JP (1) | JP2010531859A (fr) |
KR (1) | KR20100029262A (fr) |
CN (1) | CN101687777A (fr) |
AR (1) | AR070005A1 (fr) |
AU (1) | AU2008288373B2 (fr) |
BR (1) | BRPI0814402A2 (fr) |
CA (1) | CA2691586A1 (fr) |
EA (1) | EA201000083A1 (fr) |
FR (1) | FR2918372B1 (fr) |
MA (1) | MA31577B1 (fr) |
UA (1) | UA94828C2 (fr) |
WO (1) | WO2009022063A2 (fr) |
ZA (1) | ZA201000024B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102603545B (zh) * | 2012-02-10 | 2014-03-12 | 武汉万知生物医药有限公司 | 一种7-甲氧基-1-萘乙胺的制备方法 |
FR3014433B1 (fr) * | 2013-12-05 | 2015-12-25 | Servier Lab | Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997004094A1 (fr) | 1995-07-24 | 1997-02-06 | Adir Et Cie | Sequences nucleiques codant pour des recepteurs de la melatonine et leurs applications |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2689124A1 (fr) * | 1992-03-27 | 1993-10-01 | Adir | Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
FR2762598A1 (fr) * | 1997-04-25 | 1998-10-30 | Adir | Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennnent |
FR2771739B1 (fr) * | 1997-11-28 | 2001-04-20 | Adir | Nouveaux composes naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
JP3841628B2 (ja) * | 1999-08-20 | 2006-11-01 | 武田薬品工業株式会社 | 経皮吸収剤 |
FR2890562B1 (fr) * | 2005-09-09 | 2012-10-12 | Servier Lab | Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement des troubles du sommeil chez le patient deprime |
-
2007
- 2007-07-02 FR FR0704747A patent/FR2918372B1/fr not_active Expired - Fee Related
-
2008
- 2008-07-01 AU AU2008288373A patent/AU2008288373B2/en not_active Ceased
- 2008-07-01 US US12/452,429 patent/US7947852B2/en not_active Expired - Fee Related
- 2008-07-01 CA CA002691586A patent/CA2691586A1/fr not_active Abandoned
- 2008-07-01 KR KR1020107002337A patent/KR20100029262A/ko not_active Application Discontinuation
- 2008-07-01 CN CN200880022874A patent/CN101687777A/zh active Pending
- 2008-07-01 EA EA201000083A patent/EA201000083A1/ru unknown
- 2008-07-01 EP EP08827457A patent/EP2167460A2/fr not_active Withdrawn
- 2008-07-01 UA UAA201000635A patent/UA94828C2/ru unknown
- 2008-07-01 WO PCT/FR2008/000932 patent/WO2009022063A2/fr active Application Filing
- 2008-07-01 BR BRPI0814402-8A patent/BRPI0814402A2/pt not_active IP Right Cessation
- 2008-07-01 JP JP2010514037A patent/JP2010531859A/ja active Pending
- 2008-07-02 AR ARP080102856A patent/AR070005A1/es unknown
-
2010
- 2010-01-04 ZA ZA2010/00024A patent/ZA201000024B/en unknown
- 2010-02-01 MA MA32571A patent/MA31577B1/fr unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997004094A1 (fr) | 1995-07-24 | 1997-02-06 | Adir Et Cie | Sequences nucleiques codant pour des recepteurs de la melatonine et leurs applications |
Non-Patent Citations (9)
Title |
---|
"Melatonin - Clinical Perspectives", 1988, OXFORD UNIVERSITY PRESS, pages: 164 - 165 |
BRAIN RESEARCH, vol. 528, 1990, pages 170 - 174 |
CLINICAL ENDOCRINOLOGY, vol. 24, 1986, pages 359 - 364 |
INTERNATIONAL JOURNAL OF EATING DISORDERS, vol. 20, no. 4, 1996, pages 443 - 446 |
J. NEUROSURG, vol. 63, 1985, pages 321 - 341 |
NEUROPHARMACOLOGY OF PINEAL SECRETIONS, vol. 8, no. 3-4, 1990, pages 264 - 272 |
PHARMACOPSYCHIAT, vol. 20, 1987, pages 222 - 223 |
PSYCHOPHARMACOLOGY, vol. 100, 1990, pages 222 - 226 |
SCIENCE, vol. 227, 1987, pages 714 - 720 |
Also Published As
Publication number | Publication date |
---|---|
AR070005A1 (es) | 2010-03-10 |
FR2918372A1 (fr) | 2009-01-09 |
CN101687777A (zh) | 2010-03-31 |
US20100168244A1 (en) | 2010-07-01 |
AU2008288373A1 (en) | 2009-02-19 |
MA31577B1 (fr) | 2010-08-02 |
ZA201000024B (en) | 2011-04-28 |
UA94828C2 (ru) | 2011-06-10 |
KR20100029262A (ko) | 2010-03-16 |
AU2008288373B2 (en) | 2011-08-04 |
JP2010531859A (ja) | 2010-09-30 |
US7947852B2 (en) | 2011-05-24 |
WO2009022063A3 (fr) | 2009-04-16 |
CA2691586A1 (fr) | 2009-02-19 |
BRPI0814402A2 (pt) | 2015-08-04 |
FR2918372B1 (fr) | 2009-08-28 |
EA201000083A1 (ru) | 2010-06-30 |
EP2167460A2 (fr) | 2010-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008000969A1 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP2079689A2 (fr) | Derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1873140B1 (fr) | Nouveaux dérivés naphtaleniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP0994102B1 (fr) | Dérivés cycliques à chaíne cycloalkylénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
WO2006027474A2 (fr) | Nouveaux derives d ' imidazopyridine presentant une affinite vis a vis des recepteurs de la melatonine , leur procede de preparation et les compositions pharmaceutiques qui les contiennet | |
EP1466604B1 (fr) | Nouveaux dérivés d'isoquinoléine, leur procédé de préparation et leur utilisation pour traiter les troubles du système mélatoninergique | |
WO2009022063A2 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP2167457A2 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2008049996A2 (fr) | Nouveaux derives indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2593618C (fr) | Derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2009022066A2 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2009022062A1 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2005012282A1 (fr) | Nouveaux derives du benzothiofene 2-thiosubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2009022065A2 (fr) | Nouveaux derives naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1106608A1 (fr) | Nouveaux dérivés (dihydro)benzoxaziniques et (dihydro)benzothiaziniques substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
WO2005012229A1 (fr) | Nouveaux derives bicycliques alkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2010061074A1 (fr) | Derives indoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
WO2004043907A1 (fr) | Nouveaux derives du phenylnaphtalene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880022874.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08827457 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 581994 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008288373 Country of ref document: AU Ref document number: 2008827457 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2691586 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010514037 Country of ref document: JP Ref document number: 2009121918 Country of ref document: EG |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/000018 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 188/DELNP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2008288373 Country of ref document: AU Date of ref document: 20080701 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11664 Country of ref document: GE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201000083 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 20107002337 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PI 20095485 Country of ref document: MY |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12452429 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0814402 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100104 |